Profile data is unavailable for this security.
About the company
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of pharmaceutical products and aesthetic products. The Company operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The Company conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)2.38bn
- Net income in HKD-91.63m
- Incorporated2006
- Employees2.77k
- LocationSihuan Pharmaceutical Holdings Group Ltd21/F, Building 2,Zhbng 2000 Bsns CtrWest BalizhuangChaoyang DistrictBEIJING 100025ChinaCHN
- Phone+86 75 588609726
- Fax+86 1 052278758
- Websitehttps://www.sihuanpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CStone Pharmaceuticals | 230.11m | -428.53m | 9.24bn | 93.00 | -- | 23.86 | -- | 40.15 | -0.3288 | -0.3288 | 0.1776 | 0.2624 | 0.1487 | 1.38 | 1.68 | 1,704,542.00 | -27.69 | -39.13 | -54.45 | -60.19 | -12.18 | 66.69 | -186.23 | -170.86 | 1.20 | -29.83 | 0.554 | -- | -12.21 | -- | 75.16 | -- | -- | -- |
| Luye Pharma Group Ltd | 7.01bn | 451.08m | 9.67bn | 5.12k | 20.18 | 0.5452 | 6.01 | 1.38 | 0.1199 | 0.1199 | 1.86 | 4.44 | 0.2083 | 2.42 | 2.37 | 1,361,039.00 | 1.91 | 1.98 | 3.26 | 3.16 | 66.85 | 68.37 | 9.15 | 8.04 | 1.24 | 2.35 | 0.4227 | 0.00 | -1.33 | -0.9503 | -11.40 | -19.50 | -10.95 | -- |
| China Traditional Chinese Med Hldg CoLtd | 17.71bn | -300.96m | 9.77bn | 15.58k | -- | 0.4152 | 10.70 | 0.5515 | -0.0598 | -0.0598 | 3.52 | 4.67 | 0.4326 | 1.59 | 1.71 | 1,057,360.00 | -0.93 | 3.48 | -1.42 | 5.24 | 47.66 | 54.69 | -2.15 | 7.39 | 1.51 | 9.55 | 0.1333 | 21.27 | -8.90 | 2.89 | -95.79 | -49.14 | -15.28 | -48.82 |
| Hbm Holdings Ltd | 904.99m | 571.49m | 9.91bn | 210.00 | 15.38 | 4.09 | 16.57 | 10.95 | 0.741 | 0.741 | 1.15 | 2.79 | 0.3856 | 6.32 | 32.64 | 5,801,203.00 | 24.77 | -42.87 | 30.77 | -53.24 | 92.95 | 96.12 | 64.25 | -292.58 | 6.02 | 28.63 | 0.1857 | -- | -57.43 | 47.71 | -87.81 | -- | -55.31 | -- |
| Guangzhou Innogen Pharmaceutl Grp Co Ltd | -100.00bn | -100.00bn | 11.24bn | 105.00 | -- | 13.17 | -- | -- | -- | -- | -- | 1.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.39 | -- | 0.0769 | -- | -- | -- | 76.18 | -- | -- | -- |
| Fujian Haixi Pharmaceuticals Co Ltd | -100.00bn | -100.00bn | 11.41bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 47.39 | -- | 15.86 | -- | -- | -- |
| Everest Medicines Ltd | 967.41m | -748.61m | 11.98bn | 722.00 | -- | 2.49 | -- | 12.38 | -2.32 | -2.32 | 2.99 | 13.62 | 0.1684 | 13.97 | 3.04 | 1,454,751.00 | -13.03 | -29.28 | -14.21 | -31.67 | 69.92 | -- | -77.38 | -1,040.86 | 5.43 | -- | 0.1577 | -- | 461.16 | -- | -23.32 | -- | 16.96 | -- |
| Sihuan Pharmaceutical Holdings Group Ltd | 2.38bn | -91.63m | 12.80bn | 2.77k | -- | 2.58 | -- | 5.37 | -0.0098 | -0.0098 | 0.2583 | 0.542 | 0.1894 | 1.49 | 3.86 | 893,796.30 | -3.05 | -3.60 | -5.01 | -5.05 | 66.29 | 73.13 | -16.08 | -19.74 | 1.61 | -1.36 | 0.1606 | -- | 2.18 | -7.96 | -301.10 | -- | -20.58 | 3.60 |
| Consun Pharmaceutical Group Ltd | 3.71bn | 1.15bn | 14.22bn | 3.07k | 12.65 | 2.91 | 11.63 | 3.83 | 1.34 | 1.34 | 4.33 | 5.80 | 0.5642 | 2.35 | 12.33 | 1,173,505.00 | 17.60 | 14.71 | 24.67 | 22.82 | 76.62 | 75.04 | 31.20 | 29.56 | 3.32 | -- | 0.0517 | 40.93 | 14.56 | 11.42 | 16.05 | 62.72 | -9.54 | 25.83 |
| Ascletis Pharma Inc | 2.69m | -293.84m | 15.30bn | 208.00 | -- | 6.55 | -- | 5,695.75 | -0.3004 | -0.3004 | 0.0028 | 2.20 | 0.0011 | 0.2668 | 11.59 | 11,629.77 | -12.10 | -8.46 | -12.73 | -8.80 | 36.21 | 7.91 | -10,937.78 | -522.12 | 14.53 | -- | 0.0023 | -- | -97.73 | -62.52 | -107.95 | -- | -40.26 | -- |
| CF PharmTech Inc | 686.31m | 31.54m | 15.42bn | 574.00 | 489.55 | 14.17 | 149.63 | 22.47 | 0.0766 | 0.0766 | 1.67 | 2.64 | -- | -- | -- | -- | -- | -- | -- | -- | 80.18 | -- | 4.60 | -- | 1.89 | -- | 0.076 | -- | 9.23 | -- | -33.53 | -- | -- | -- |
| Zai Lab Ltd | 3.60bn | -1.37bn | 15.44bn | 1.78k | -- | 2.71 | -- | 4.29 | -1.25 | -1.25 | 3.29 | 5.06 | 0.3903 | 3.12 | 4.81 | -- | -14.89 | -30.44 | -21.37 | -36.84 | 61.15 | 63.11 | -38.15 | -128.85 | 2.27 | -- | 0.2223 | -- | 15.33 | 56.54 | 31.73 | -- | 4.70 | -- |
| Vigonvita Life Sciences Co Ltd | -100.00bn | -100.00bn | 16.58bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -94.07 | -- | -1,848.73 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 165.97m | 1.78% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 80.05m | 0.86% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 68.54m | 0.74% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 50.85m | 0.55% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 39.28m | 0.42% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 32.17m | 0.35% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 16.39m | 0.18% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 11.70m | 0.13% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 11.12m | 0.12% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 10.35m | 0.11% |
